CL2013000788A1 - Compuestos derivados de 1,2,4-oxadiazol, inhibidores de la proteina activadora de 5-lipoxigenasa (flap); composicion farmaceutica; metodo de tratamiento; y uso para el tratamiento de un trastorno mediado por leucotrienos tal como enfermedades cardiovasculares, inflamatorias, alergicas, pulmonares y fibroticas, renales y cancer. - Google Patents

Compuestos derivados de 1,2,4-oxadiazol, inhibidores de la proteina activadora de 5-lipoxigenasa (flap); composicion farmaceutica; metodo de tratamiento; y uso para el tratamiento de un trastorno mediado por leucotrienos tal como enfermedades cardiovasculares, inflamatorias, alergicas, pulmonares y fibroticas, renales y cancer.

Info

Publication number
CL2013000788A1
CL2013000788A1 CL2013000788A CL2013000788A CL2013000788A1 CL 2013000788 A1 CL2013000788 A1 CL 2013000788A1 CL 2013000788 A CL2013000788 A CL 2013000788A CL 2013000788 A CL2013000788 A CL 2013000788A CL 2013000788 A1 CL2013000788 A1 CL 2013000788A1
Authority
CL
Chile
Prior art keywords
treatment
leukotriene
fibrotic
oxadiazole
allergic
Prior art date
Application number
CL2013000788A
Other languages
English (en)
Inventor
Alessandra Bartolozzi
Todd Bosanac
Lombaert Stephane De
John D Huber
Pui Leng Loke
Weimin Liu
Alan Olague
Doris Riether
Heather Tye
Lifen Wu
Zhindong Chen
Jonathon Alan Dines
Tina Marie Morwick
Renee M Zindell
Original Assignee
Boheringer Ingelheim Internat Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44720163&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013000788(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boheringer Ingelheim Internat Gmbh filed Critical Boheringer Ingelheim Internat Gmbh
Publication of CL2013000788A1 publication Critical patent/CL2013000788A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Compuestos derivados de 1,2,4-oxadiazol, inhibidores de la proteína activadorea de 5-lipoxigenasa (Flap); composición farmacéutica; método de tratamiento; y uso para el tratamiento de un trastorno mediado por leucotrienos tal como enfermedades cardiovasculares, inflamatorias, alérgicas, pulmonares y fibróticas, renales y cáncer.
CL2013000788A 2010-09-23 2013-03-21 Compuestos derivados de 1,2,4-oxadiazol, inhibidores de la proteina activadora de 5-lipoxigenasa (flap); composicion farmaceutica; metodo de tratamiento; y uso para el tratamiento de un trastorno mediado por leucotrienos tal como enfermedades cardiovasculares, inflamatorias, alergicas, pulmonares y fibroticas, renales y cancer. CL2013000788A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38573310P 2010-09-23 2010-09-23
US201161533349P 2011-09-12 2011-09-12

Publications (1)

Publication Number Publication Date
CL2013000788A1 true CL2013000788A1 (es) 2013-06-28

Family

ID=44720163

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013000788A CL2013000788A1 (es) 2010-09-23 2013-03-21 Compuestos derivados de 1,2,4-oxadiazol, inhibidores de la proteina activadora de 5-lipoxigenasa (flap); composicion farmaceutica; metodo de tratamiento; y uso para el tratamiento de un trastorno mediado por leucotrienos tal como enfermedades cardiovasculares, inflamatorias, alergicas, pulmonares y fibroticas, renales y cancer.

Country Status (18)

Country Link
US (1) US8575201B2 (es)
EP (1) EP2619197B1 (es)
JP (1) JP5713511B2 (es)
KR (1) KR20130109122A (es)
CN (1) CN103261193A (es)
AU (1) AU2011305667A1 (es)
BR (1) BR112013008638A2 (es)
CA (1) CA2812449A1 (es)
CL (1) CL2013000788A1 (es)
CO (1) CO6710902A2 (es)
EA (1) EA201300389A1 (es)
EC (1) ECSP13012548A (es)
IN (1) IN2013DN02555A (es)
MX (1) MX2013003202A (es)
PE (1) PE20131398A1 (es)
SG (1) SG188604A1 (es)
WO (1) WO2012040139A1 (es)
ZA (1) ZA201301747B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012027322A1 (en) * 2010-08-26 2012-03-01 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
JP5828188B2 (ja) * 2010-09-23 2015-12-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン産生のオキサジアゾール阻害剤
WO2012040139A1 (en) 2010-09-23 2012-03-29 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
AR089853A1 (es) 2012-02-01 2014-09-24 Boehringer Ingelheim Int Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso
US9745328B2 (en) * 2013-02-04 2017-08-29 Janssen Pharmaceutica Nv Flap modulators
EP2875736B1 (en) 2013-11-26 2016-07-27 Citrage N-Carbamoylputrescine to enhance muscle protein synthesis

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60026312T2 (de) 1999-08-06 2006-12-21 Janssen Pharmaceutica N.V. Interleukin-5 hemmende 6-azauracil derivate
WO2005039485A2 (en) * 2003-08-13 2005-05-06 Chiron Corporation Gsk-3 inhibitors and uses thereof
US7319108B2 (en) 2004-01-25 2008-01-15 Sanofi-Aventis Deutschland Gmbh Aryl-substituted heterocycles, process for their preparation and their use as medicaments
CA2584262A1 (en) 2004-10-18 2006-04-27 Merck & Co., Inc. Diphenyl substituted alkanes as flap inhiibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) * 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
AU2007238878A1 (en) * 2006-04-11 2007-10-25 Merck Sharp & Dohme Corp. Diaryl substituted alkanes
ES2376396T3 (es) 2006-06-26 2012-03-13 Amgen Inc. Método para tratar aterosclerosis.
ATE543810T1 (de) * 2006-09-01 2012-02-15 Merck Sharp & Dohme Hemmer des 5-lipoxygenase aktivierenden proteins (flap)
EP2148878A4 (en) 2007-04-20 2011-08-10 Merck Canada Inc NEW HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME-A-DELTA-9-DESATURASE
WO2008156721A1 (en) 2007-06-20 2008-12-24 Merck & Co., Inc. Diphenyl substituted alkanes
CA2702225A1 (en) 2007-10-10 2009-04-16 Merck Sharp & Dohme Corp. Diphenyl substituted cycloalkanes
DE102008037790A1 (de) * 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
CA2741666C (en) * 2008-10-31 2017-04-11 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
CA2749893A1 (en) 2009-02-04 2010-08-12 Pfizer Inc. 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6h)-one derivatives
MX2012013031A (es) 2010-05-12 2012-12-17 Univ Vanderbilt Potenciadores alostericos mglur4 de sulfona heterociclica, composiciones y metodos para tratar disfuncion neurologica.
SG187549A1 (en) * 2010-08-16 2013-03-28 Boehringer Ingelheim Int Oxadiazole inhibitors of leukotriene production
WO2012027322A1 (en) * 2010-08-26 2012-03-01 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
WO2012040139A1 (en) 2010-09-23 2012-03-29 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
JP5828188B2 (ja) * 2010-09-23 2015-12-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン産生のオキサジアゾール阻害剤

Also Published As

Publication number Publication date
MX2013003202A (es) 2013-04-24
KR20130109122A (ko) 2013-10-07
JP5713511B2 (ja) 2015-05-07
EP2619197A1 (en) 2013-07-31
PE20131398A1 (es) 2013-12-19
CN103261193A (zh) 2013-08-21
SG188604A1 (en) 2013-04-30
EA201300389A1 (ru) 2013-09-30
WO2012040139A1 (en) 2012-03-29
ECSP13012548A (es) 2013-06-28
ZA201301747B (en) 2014-08-27
US8575201B2 (en) 2013-11-05
JP2013537909A (ja) 2013-10-07
CO6710902A2 (es) 2013-07-15
IN2013DN02555A (es) 2015-08-07
EP2619197B1 (en) 2015-08-05
CA2812449A1 (en) 2012-03-29
BR112013008638A2 (pt) 2016-06-21
US20120295896A1 (en) 2012-11-22
AU2011305667A1 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
CL2013000455A1 (es) Compuestos derivados oxadiazol, inhibidores de la produccion de leucotrienos; composicion farmaceutica que lo comprende; y su uso en el tratamiento de enfermedades cardiovasculares, inflamatorias, alergicas, pulmonares y fibroticas y cancer.
CL2015000829A1 (es) Inhibidores de histona desmetilasas
CL2012003722A1 (es) Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida.
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2013000016A1 (es) Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
CL2017002283A1 (es) Formulaciones de anticuerpos y métodos (divisional de solicitud n°1081-2014)
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
BR112015011112A2 (pt) composto oligomérico, oligômero, composição farmacêutica, uso do composto oligomérico, método de síntese de um composto oligomérico e método de tratamento de uma doença.
JP2011256183A5 (es)
CL2011003229A1 (es) Compuestos conjugados derivados de criptoficina; procedimiento de preparacion; y su uso para el tratamiento del cancer.
EA201400838A1 (ru) ЗАМЕЩЕННЫЕ АМИДИНОМ β-ЛАКТАМЫ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В КАЧЕСТВЕ АНТИБАКТЕРИАЛЬНЫХ СРЕДСТВ
BR112012022878A2 (pt) composto, composição farmacêutica, uso do compostos e método de tratamento
EA201000774A1 (ru) Ингибиторы бета-лактамазы
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
EA201400579A1 (ru) Антитела к il-36r
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
AR089993A1 (es) Macrociclos peptidomimeticos
MX2021001169A (es) Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acético, composiciones, y usos de las mismas.
AR090339A1 (es) Metodos de pronostico, diagnostico y tratamiento de la fibrosis pulmonar idiopatica
CL2008001373A1 (es) Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer.
CL2013000788A1 (es) Compuestos derivados de 1,2,4-oxadiazol, inhibidores de la proteina activadora de 5-lipoxigenasa (flap); composicion farmaceutica; metodo de tratamiento; y uso para el tratamiento de un trastorno mediado por leucotrienos tal como enfermedades cardiovasculares, inflamatorias, alergicas, pulmonares y fibroticas, renales y cancer.
BR112012022879A2 (pt) composto, composição farmacêutica, uso do composto e método de tratamento
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
CL2008002369A1 (es) Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer.
BR112013011448A2 (pt) composto, composição farnmacêutica, e, uso do composto